compounded glp 1 ban GLP-1 ban: What providers need to know FDA says that the GLP-1

Our vegan, gluten-free, soy-free, and preservative-free capsules use acid-resistant technology to deliver probiotics directly to your gut

By exploring human studies and mechanistic insights, this review underscores irisins potential to address global health challenges, such as obesity and type 2 diabetes, while advancing strategies for personalized exercise interventions.

The yerba mate market size is projected to grow from $2.29 billion in 2026 to $3.58 billion by 2034, at a CAGR of 5.72% during the forecast period 2026-2034.

The WHO released new guidance on GLP-1 medications for adults with obesity, recommending their long-term, continuous usewhen clinically appropriate.

Rhode Island's Medicaid agency proposes ending GLP-1 coverage for weight loss while keeping diabetes uses, citing soaring costs.

Link to full post: GLP-1 Drugs, Digital Health & Obesity Trends in 2026Overweight and obesity are driving a booming digital health market through telehealth, wearables, and new pharma-to-consumer models.I've been reporting on this space in my #Trends report since March 2024two years ago (Navigating Obesity Care in the Digital Age)